PURPOSE
Immunotherapy with chemotherapy significantly improves progression-free survival in advanced endometrial cancer (EC), especially in microsatellite instability-high (MSI-H) cases. Despite this, for recurrent EC in the postimmunotherapy setting, new treatment options are urgently needed. The PI3K pathway is frequ...
A. Passarelli, G. L. Scaglione, D. Califano et al.· JCO Precision Oncology· 0 citations
The therapeutic landscape of HER2-positive metastatic breast cancer (HER2-positive mBC) has been transformed by increasingly effective HER2-directed therapies. Following the establishment of trastuzumab and pertuzumab as first-line standard treatment, highly active antibody-drug conjugates (ADCs), particularly trastuzu...
M. Palleschi, A. Viansone, Filippo Merloni et al.· Cancer Treatment Reviews· 0 citations
OBJECTIVE
As treatment strategies evolve in advanced or metastatic endometrial cancer (EC), quality of life (QoL) has become a key parameter in evaluating therapeutic value. This systematic review summarizes QoL outcomes from pivotal trials that have shaped clinical practice in advanced EC.
METHODS
Data from phase II...
V. Tuninetti, A. Farolfi, Simona Butticè et al.· Tumori· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
